Combination approach can improve the success rate of cancer treatment

Combination approach can improve the success rate of cancer treatment
A new cancer vaccine could boost the positive effects of existing immunotherapy drugs, improving the success rate of treatments from 20% to 75% of cases, according to a new study by immunologists from the University of Konstanz.
The vaccine, which incorporates a new immunostimulant that is safe for use in humans, was shown to partially eliminate tumors in mice. However, the study further demonstrated that combining the vaccine with an immune checkpoint inhibitor — an established immunotherapy drug with a 20% success rate overall for patients — can vastly improve the proportion of individuals who respond to treatments, eliminating tumors in 75% of cases in mice.

Related Keywords

Germany ,Netherlands ,Konstanz ,Baden Wüberg ,Dennis Horvath ,Marcus Groettrup ,Julia Koerner ,Emily Henderson ,Riboxx Pharmaceuticals In Dresden ,Nature Communications On ,University Of Konstanz ,Nature Communications ,Professor Marcus Groettrup ,Study Senior Author ,Riboxx Pharmaceuticals ,Advanced Study ,Collective Behaviour ,Cancer ,Cancer Therapy ,Fell ,Drugs ,Immune Response ,Immunotherapy ,Melanoma ,Stress ,Vaccine ,ஜெர்மனி ,நெதர்லாந்து ,டென்னிஸ் ஹார்வத் ,ஜூலியா கொஏர்நேற் ,எமிலி ஹென்டர்சன் ,இயற்கை தகவல்தொடர்புகள் ஆன் ,இயற்கை தகவல்தொடர்புகள் ,படிப்பு மூத்தவர் நூலாசிரியர் ,கூட்டு நடத்தை ,புற்றுநோய் ,விரிப்புகள் ,